

Srishti Kumar

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/925619/srishti-kumar-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

9
papers

9
citations

2
h-index

3
g-index

10
ext. papers

19
ext. citations

3.5
avg, IF

0.05
L-index

#	Paper	IF	Citations
9	The optimal timing of allogeneic stem cell transplantation for primary myelofibrosis.. <i>Transplantation and Cellular Therapy</i> , 2022 ,		1
8	Decision Analysis of Allogeneic Stem Cell Transplantation for Primary Myelofibrosis. <i>Blood</i> , 2021 , 138, 2923-2923	2.2	
7	Audit feedback interventions to address high-risk prescriptions in long-term care homes: a costing study and return on investment analysis. <i>Implementation Science Communications</i> , 2021 , 2, 125	2.2	1
6	Total Shoulder Arthroplasty Is Cost-Effective Compared with Hemiarthroplasty: A Real-World Economic Evaluation. <i>Journal of Bone and Joint Surgery - Series A</i> , 2021 , 103, 1499-1509	5.6	0
5	Return on Investment Analysis for the Integrated Parkinsons Care Network: Lesson Learned from a Pilot Study. <i>Journal of Parkinson's Disease</i> , 2021 , 11, 2085-2091	5.3	
4	Cost-effectiveness of Endoscopic Polypectomy in Clinic compared to Endoscopic Sinus Surgery: A modelling study. <i>Clinical Otolaryngology</i> , 2020 , 45, 477-485	1.8	2
3	Economic Analysis of Exclusive Human Milk Diets for High-Risk Neonates, a Canadian Hospital Perspective. <i>Breastfeeding Medicine</i> , 2020 , 15, 377-386	2.1	1
2	Cost-Utility Analysis of Apixaban Compared to Usual Care for the Primary Thromboprophylaxis of Ambulatory Cancer Patients Initiating Chemotherapy. <i>Blood</i> , 2019 , 134, 329-329	2.2	
1	In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. <i>Thrombosis Research</i> , 2018 , 171, 97-102	8.2	4